Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TQ-A3334 Tablet After Multiple Doses in Healthy Adult Subjects
Latest Information Update: 04 Nov 2024
At a glance
- Drugs AL-034 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 30 Oct 2024 Status changed from recruiting to completed.
- 29 Dec 2023 Status changed from not yet recruiting to recruiting.
- 12 Dec 2023 New trial record